Aptinyx Set in Motion Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder
Synopsis: Aptinyx Inc., a clinical-stage biopharmaceutical company, announced the initiation of a phase 2b study evaluating 50 mg QD of NYX-783 in…
Synopsis: Aptinyx Inc., a clinical-stage biopharmaceutical company, announced the initiation of a phase 2b study evaluating 50 mg QD of NYX-783 in…